Amyloidosis Research Consortium Inc

Analysis

Amyloidosis Research Consortium Inc is a registered charity in United States, based in Newton, MA. It received its IRS tax-exemption ruling in August 2015, 11 years ago. Its declared purposes cover medical research, which this site groups under health and saving lives. The IRS classifies it as a publicly supported organisation (donations from the general public) under section 501(c)(3), and contributions to it are listed as tax-deductible.

In the financial year ending December 2023, Amyloidosis Research Consortium Inc reported income of $2.9m and spending of $2.4m, spending 84% of its income. Across the 5 years on record, from December 2019 to December 2023, income grew from $1.7m to $2.9m (+70%), an average of +14% a year. The sharpest change came in the year to December 2022, when income rose by 37%. Over the whole period it spent 83% of the income it received.

Among 40,470 United States charities whose main cause is health and saving lives and that reported income, Amyloidosis Research Consortium Inc sits at the 75th percentile: it is larger than about 75% of them. Against every charity in United States with reported income it ranks in the 89th percentile, and in the 88th percentile within MA. Charities of a similar size with the same main cause include Legacy Foundation of Kentuckiana Inc ($2.9m), Ivi Foundation Inc ($2.9m) and Childrens Theraplay Foundation Inc ($2.9m).

On its Form 990 for the period ending December 2023, revenue came from contributions and grants 94% and program service revenue 0.1% of the total. Compensation of current officers, directors and key employees was $178k (7.4% of expenses). Other salaries and wages came to $1.1m. At year end it held assets of $3.0m against liabilities of $227k, net assets of $2.7m. It reported 17 employees.